Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.
Technology developed by GTX Medical has shown astonishing results in paralysed patients. Monetising it might be an even more impressive achievement.
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.